Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer-Reference-Cited by-同舟云学术

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

Published:2010-07-01 Issue:7 Volume:120 Page:2406-2413
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Miller Todd W.,Hennessy Bryan T.,González-Angulo Ana M.,Fox Emily M.,Mills Gordon B.,Chen Heidi,Higham Catherine,García-Echeverría Carlos,Shyr Yu,Arteaga Carlos L.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference41 articles.

1. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

2. Estrogen-Independent Proliferation Is Present in Estrogen-Receptor HER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole

3. HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer

4. A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer

5. Activation of Mitogen-Activated Protein Kinase in Xenografts and Cells during Prolonged Treatment with Aromatase Inhibitor Letrozole

Cited by 455 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110α degradation;2024-08-17

2. A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer;Clinical Breast Cancer;2024-08

3. Inactivated cGAS‐STING Signaling Facilitates Endocrine Resistance by Forming a Positive Feedback Loop with AKT Kinase in ER+HER2– Breast Cancer;Advanced Science;2024-07-18

4. Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer;Cancer Chemotherapy and Pharmacology;2024-06-27

5. BOLERO-5: a phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER + /HER2- advanced breast cancer;Discover Oncology;2024-06-21